Abstract:Anti-bacterial monoclonal antibody (mAb) therapies either rely on toxin neutralization or opsonophagocytic killing (OPK). Toxin neutralization protects the host from toxin-induced damage, while leaving the organism intact. OPK inducing antibodies clear the bacteria but leave the released toxins unencountered. Infection site targeted anti-toxin antibodies (ISTAbs) that we report here addresses this binary paradigm by combining both functionalities into a single molecule. ISTAbs consist of cell wall targeting (CWT) domains of bacteriophage endolysins fused to toxin neutralizing mAbs (IgG). CWT governs specific binding to the surface of bacteria while the IgG variable domain neutralizes the toxins as they are released. The complex is then cleared by phagocytic cells. As proof of concept, we generated several ISTAb prototypes targeting major toxins from two Gram-positive spore forming pathogens that have a high clinical significance; Clostridium difficile, causative agent of the most common hospital-acquired infection, and Bacillus anthracis, a Category A select agent pathogen. Both groups of ISTAbs exhibited potent toxin neutralization, binding to their respective bacterial cells, and induction of opsonophagocytosis. In mice infected with B. anthracis, ISTAbs exhibit significantly higher efficacy than parental IgG in both pre- and post-challenge models. Furthermore, ISTAbs fully protected against B. anthracis infection in a nonhuman primate (NHP) aerosol challenge model. These findings establish that as a platform technology, ISTAbs are broadly applicable for therapeutic intervention against several toxigenic bacterial pathogens.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new type of antibody therapy to simultaneously achieve toxin neutralization and bacterial clearance, so as to more effectively combat bacterial infections. Specifically, the researchers designed an engineered antibody called "Infection Site Targeted Anti - toxin Antibodies (ISTAbs)". This antibody combines the Cell Wall Targeting (CWT) domain with a toxin - neutralizing monoclonal antibody (IgG) to form a single molecule, which can both neutralize the toxins released by bacteria and clear the bacteria through phagocytosis. ### Background problems 1. **Limitations of traditional antibody therapies** - **Toxin - neutralizing antibodies**: They can only protect the host from toxin damage, but cannot clear bacteria. - **Opsonophagocytic bactericidal antibodies**: They can clear bacteria, but are powerless against the released toxins. 2. **Antibiotic resistance problem**: With the emergence of multi - drug - resistant bacteria, the effectiveness of traditional antibiotic therapies is gradually decreasing, and new treatment strategies are urgently needed. ### Solutions - **Design concept of ISTAbs**: By fusing CWT and toxin - neutralizing antibodies, ISTAbs can specifically bind to the bacterial surface at the infection site and neutralize the toxins released by it. Subsequently, these complexes can be phagocytosed and cleared by immune cells (such as neutrophils). ### Research objects - **Bacillus anthracis**: A class A select pathogen with high clinical significance. - **Clostridium difficile**: One of the most common pathogens of hospital - acquired infections. ### Experimental verification - **In vitro experiments**: Verify the toxin - neutralizing ability, bacterial - binding ability and opsonophagocytic activity of ISTAbs. - **Animal model experiments**: Evaluate the efficacy of ISTAbs in mice and non - human primates, especially in the prevention and treatment of anthrax infection. ### Conclusions - **Significantly improved efficacy**: Compared with traditional monoclonal antibodies, ISTAbs show higher effectiveness and lower bacterial load in the prevention and treatment of anthrax infection. - **Wide applicability**: As a platform technology, the concept of ISTAbs is applicable to a variety of toxin - driven bacterial infections and has broad clinical application prospects. ### Formula example To ensure the completeness of the answer, here is a formula example involved in the article: - **Affinity Constant (\(K_D\))**: \[ K_D=\frac{k_{\text{off}}}{k_{\text{on}}} \] where \(k_{\text{on}}\) is the binding rate constant and \(k_{\text{off}}\) is the dissociation rate constant. In this way, this study shows that ISTAbs, as an innovative immunotherapy, has great potential in combating bacterial infections.

Engineered antibodies targeted to bacterial surface integrate effector functions with toxin neutralization to provide superior efficacy against bacterial infections

Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications

Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae

Study on the Preparation of the Immunotoxin 2E8-NCTD and Its Targeting Killing Effect in Vitro.

Cascade-Targeted Nanoplatforms for Synergetic Antibiotic/ROS/NO/Immunotherapy against Intracellular Bacterial Infection

IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Development of Host-Cleavable Antibody-Bactericide Conjugates against Extracellular Pathogens

Hyperimmune Targeting Staphylococcal Toxins Effectively Protect Against USA 300 MRSA Infection in Mouse Bacteremia and Pneumonia Models

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo

Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies

A novel therapeutic antibody screening method using bacterial high-content imaging reveals functional antibody binding phenotypes of Escherichia coli ST131

Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization

Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii

Mechanism of Action for an All-in-One Monoclonal Antibody Against Staphylococcus Aureus Infection.

Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination

Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling

Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators

An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies